Roche sells off its strug­gling IL-13 drug le­brik­izum­ab in $1.4B Der­mi­ra deal

Af­ter watch­ing its late-stage asth­ma pro­gram for its IL-13 drug le­brik­izum­ab floun­der with mixed and marked­ly unim­pres­sive re­sults, Roche is out­li­cens­ing the bulk of the de­vel­op­ment rights to Der­mi­ra $DERM in a $1.4 bil­lion deal — which starts off with $135 mil­lion in near-term cash.

Der­mi­ra is plan­ning to hus­tle its new drug di­rect­ly in­to a Phase IIb study for atopic der­mati­tis so it can line up a dose as quick­ly as pos­si­ble that re­searchers can take in­to Phase III.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.